In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on NanoString Tech (NSTG – Research Report), with a price target of $28.00. The company’s shares opened today at $15.66.
According to TipRanks, Savant is an analyst with an average return of -3.4% and a 40.79% success rate. Savant covers the Healthcare sector, focusing on stocks such as NanoString Tech, Guardant Health, and Maravai Lifesciences Holdings.
NanoString Tech has an analyst consensus of Strong Buy, with a price target consensus of $30.60.
The company has a one-year high of $62.56 and a one-year low of $11.12. Currently, NanoString Tech has an average volume of 877.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.
Read More on NSTG:
- Morgan Stanley Keeps Their Sell Rating on Shift4 Payments (FOUR)
- Yelp (YELP) Receives a Rating Update from a Top Analyst
- Doximity (DOCS) Receives a Buy from Goldman Sachs
- Morgan Stanley Reaffirms Their Buy Rating on Ingersoll Rand (IR)
- Morgan Stanley Sticks to Their Buy Rating for New Fortress Energy (NFE)